MiniMed Group Inc (NASDAQ:MMED) Given Consensus Rating of “Moderate Buy” by Brokerages

MiniMed Group Inc (NASDAQ:MMED) has earned an average recommendation of “Moderate Buy” from the thirteen brokerages that are presently covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold rating and eleven have issued a buy rating on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $22.4545.

A number of research firms have recently commented on MMED. The Goldman Sachs Group began coverage on shares of MiniMed Group in a research report on Tuesday, March 31st. They issued a “buy” rating and a $24.00 price target on the stock. Mizuho began coverage on shares of MiniMed Group in a research report on Tuesday, March 31st. They issued an “outperform” rating and a $21.00 price target on the stock. Evercore began coverage on shares of MiniMed Group in a research report on Tuesday, March 31st. They issued an “outperform” rating and a $20.00 price target on the stock. Piper Sandler began coverage on shares of MiniMed Group in a research report on Tuesday, March 31st. They issued a “neutral” rating and a $16.00 price target on the stock. Finally, BTIG Research began coverage on shares of MiniMed Group in a research report on Tuesday, March 31st. They issued a “buy” rating and a $25.00 price target on the stock.

MiniMed Group Stock Down 3.2%

NASDAQ MMED opened at $13.20 on Friday. MiniMed Group has a 12-month low of $12.80 and a 12-month high of $20.48.

MiniMed Group (NASDAQ:MMED) last posted its earnings results on Friday, April 17th. The company reported $999.00 earnings per share (EPS) for the quarter.

MiniMed Group Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.